Lv1
78 积分 2024-11-13 加入
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
13天前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
29天前
已完结
The treatment of marginal zone lymphoma
1个月前
已完结
Drug development in MZL: caring for the forgotten child
1个月前
已关闭
A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system
2个月前
已完结
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
2个月前
已完结
Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective Study
3个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
4个月前
已完结
International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma
4个月前
已完结
皖公网安备34019202002308
